Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.
about
In vivo pharmacodynamic characterization of a novel plectasin antibiotic, NZ2114, in a murine infection modelEfficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis.Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.Dihydrostreptomycin or streptomycin in combination with penicillin G in dairy cattle therapeutics: a review and re-analysis of published data. Part 1: clinical pharmacology.Comparative pharmacokinetics of ceftaroline in rats, rabbits, and monkeys following a single intravenous or intramuscular injection.Pharmacodynamics of ampicillin-sulbactam in an in vitro infection model against Escherichia coli strains with various levels of resistance.In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteriaIn vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations.In vivo bactericidal activities of ciprofloxacin and pefloxacin in an experimental model of Serratia marcescens endocarditis.In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia modelPharmacodynamics of cefquinome in a neutropenic mouse thigh model of Staphylococcus aureus infectionPharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administrationIn vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infectionPharmacokinetics-pharmacodynamics of a sordarin derivative (GM 237354) in a murine model of lethal candidiasisValidation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection.Improved efficacy of ciprofloxacin administered in polyethylene glycol-coated liposomes for treatment of Klebsiella pneumoniae pneumonia in rats.Simplified dosing of gentamicin for treatment of sepsis in Bangladeshi neonates.An imported enteric fever caused by a quinolone-resistant Salmonella Typhi.Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model.Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection modelsPharmacodynamics of moxifloxacin against Streptococcus pyogenes in an in vitro kinetic model.Determination of antibiotic effect in an in vitro pharmacodynamic model: comparison with an established animal model of infectionIn vivo pharmacodynamics of a new oxazolidinone (linezolid)Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.In vivo activity of cefquinome against Escherichia coli in the thighs of neutropenic miceImpact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection modelsIn vivo pharmacodynamics of new lipopeptide MX-2401In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.Nonlinear pharmacokinetics of piperacillin in healthy volunteers--implications for optimal dosage regimensWhat do we really know about antibiotic pharmacodynamics?Pharmacodynamics of a new cephalosporin, PPI-0903 (TAK-599), active against methicillin-resistant Staphylococcus aureus in murine thigh and lung infection models: identification of an in vivo pharmacokinetic-pharmacodynamic target.Pharmacokinetics of cefovecin in cynomolgus macaques (Macaca fascicularis), olive baboons (Papio anubis), and rhesus macaques (Macaca mulatta)Pharmacokinetics and antibacterial activity of daily gentamicin.Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis.Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.Determination of robust ocular pharmacokinetic parameters in serum and vitreous humor of albino rabbits following systemic administration of ciprofloxacin from sparse data sets by using IT2S, a population pharmacokinetic modeling program.Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
P2860
Q24654780-CE9FFF05-F978-4B0B-A553-32B63CCC19AAQ28345165-95AC754F-478D-4B45-955F-224A014EF6D9Q30326190-37BD4E9C-175A-4F38-B6FF-2B7979E9882EQ30995411-4CD20B05-64DE-4C20-B518-70B75F2729DFQ33613654-109E1A49-BA0C-464E-81E2-21E4868DC563Q33689403-4AB3B274-A702-4153-9FA8-0B30A3C83104Q33696946-C942F83E-A41A-4915-BA2C-C36ADD59C3F3Q33697003-B1B247FF-F6A2-4936-91E7-9185153A2CBAQ33753649-DCD65829-08FB-41DD-833A-8CAD79F57131Q33757851-63C398F5-7DDC-417C-A9CB-9A799AD836DFQ33797936-6B9B89A1-B5CD-4BEF-8F25-DB5ACD4022C2Q33979054-3D7C012A-AB88-4792-9619-CDE83E4C4B55Q33979123-4B04634E-4F8D-4351-9137-0285942F7964Q33979426-CEEB7FF7-6CEA-45F6-B90C-3FEEDAFEF96FQ33980421-DAD6FAEF-857D-4610-84BE-5AF03E59EEDDQ33981143-5CF344AA-8AEF-46E3-B767-B06A184055DFQ33982098-CC28D09B-E6D7-4C8A-A226-EE28C29E91B7Q34083485-7138B52A-ED83-4410-8A99-176ECFABFAA2Q34099282-625F04D4-9AC3-4BA0-A117-8DB033DC52B5Q34107991-CD49EAF4-EE55-4831-AEEC-56DE6EB621DBQ34108149-1797093D-1A16-4AD7-BFD4-B2952B134691Q34108406-BA3193D0-2705-4C0C-BD4F-7722DB15087BQ34141627-89CB9BBC-7458-42FE-89FE-9A97CC792285Q34142754-C96AEE63-EB29-4249-A3E6-B799AEB7BC95Q34230600-05BC8F28-6EAB-420C-9F9E-3F3F5740B290Q34244192-7889D847-C352-40AA-A02B-FC401B31626CQ34299028-9228892A-2EDC-459D-9F50-142E3BE6945AQ34299064-B0593BA5-1FA9-4F1B-BA49-2732E34459E2Q34301626-466A48C5-76C6-454D-87A7-3EB36CF93AC9Q34309486-5F08A923-FF88-4DAB-B681-8F1CF8DFEE7CQ34320027-EFB61C30-39E5-40F4-97C7-F47017991A54Q34381321-402D06BD-B07E-49E6-9581-3A46C7F3D4E8Q34443407-4B1CB92A-56A5-459F-A1AB-4381B5A977DCQ34510488-134D0FEE-E062-4E50-A0E2-F9B113F27672Q35010834-AB3D83EC-17E8-4D0D-B4A0-AB610459C851Q35066606-67A60757-9DD8-4D2F-B2FA-EDA1385FC1B3Q35102656-4E85E4E8-FB84-450A-A9D1-0B1B6A2FA840Q35115070-D4EA6F03-B40F-40B3-A89B-76783C7B9DC8Q35116889-C8610597-C268-4A18-90B3-4B8DE848B490Q35117352-C2FFD7AF-2194-491A-ABC0-89E37BE38B54
P2860
Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Comparative antibiotic dose-ef ...... is and thigh-infection models.
@en
Comparative antibiotic dose-ef ...... is and thigh-infection models.
@nl
type
label
Comparative antibiotic dose-ef ...... is and thigh-infection models.
@en
Comparative antibiotic dose-ef ...... is and thigh-infection models.
@nl
prefLabel
Comparative antibiotic dose-ef ...... is and thigh-infection models.
@en
Comparative antibiotic dose-ef ...... is and thigh-infection models.
@nl
P2093
P356
P1476
Comparative antibiotic dose-ef ...... is and thigh-infection models.
@en
P2093
Leggett JE
Vogelman B
P304
P356
10.1093/INFDIS/159.2.281
P407
P577
1989-02-01T00:00:00Z